Advertisement

Topics

Latest "Ovid Therapeutics" News Stories

13:50 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "Ovid Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Ovid Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Ovid Therapeutics for you to read. Along with our medical data and news we also list Ovid Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ovid Therapeutics Companies for you to search.

Showing "Ovid Therapeutics" News Articles 1–25 of 8,100+

Extremely Relevant

Ovid Therapeutics (OVID) Presents At Baird's Global Healthcare Conference - Slideshow


Ovid Therapeutics (OVID) Presents At Jefferies 2018 Global Healthcare Conference - Slideshow

Ovid Therapeutics Plans to Move into the Phase 3 Trial Based on End-of-Phase 2 Meeting for OV101

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced plans to move ahead with a single pivotal Phase 3 trial of OV101 in pediatric patients with Angelman syndrome based on its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). … Continued The pos...


Ovid Therapeutics Drug, Invented 41 Years Ago, May Help People With A Rare Disorder

This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.

Ovid Therapeutics starts ELEKTRA and ARCADE trials for rare epilepsies

Ovid Therapeutics has commenced two Phase ll ELEKTRA and ARCADE trials of OV935/TAK-935 for the treatment of paediatric patients with...Read More... The post Ovid Therapeutics starts ELEKTRA and ARCADE trials for rare epilepsies appeared first on Drug Development Technology.

Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced additional exploratory efficacy data and analyses from the company’s Phase 2 STARS trial that further support the potential of OV101, a novel selective extrasynaptic GABAA receptor agonist that is being investigated to...

Positive Results For Ovid Drug, But Questions Remain

This morning, Ovid Therapeutics, a small biotechnology company, is announcing data indicating that a drug, gaboxadol, may be of some help for patients with a condition called Angelman Syndrome.

Relevant

Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significa...

Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.

Takeda and Ovid partner to start TAK-935/OV935 clinical trials

Takeda Pharmaceutical Company, in collaboration with Ovid Therapeutics, is set to begin three clinical trials of TAK-935/OV935 to treat a...Read More... The post Takeda and Ovid partner to start TAK-935/OV935 clinical trials appeared first on Drug Development Technology.

$OVID Initiaties Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies https://finance.yahoo.com/news/ovid-therapeutics-announces-initiation-two-123000315.html …

$OVID Initiaties Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies https://finance.yahoo.com/news/ovid-therapeutics-announces-initiation-two-123000315.html …

Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Takeda and partner Ovid are planning new trials in rare pediatric indications for their first-in-class epilepsy drug, including in the...  

Takeda, Ovid plan to launch three trials of anti-epileptic drug TAK-935/OV935

Takeda Pharmaceutical and Ovid Therapeutics have revealed details of a clinical development program of their anti-epileptic drug TAK-935/OV935 in rare developmental and epileptic encephalopathies (DEE).

AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3

Today's Daily Dose brings you news about stock offering of Assembly Biosciences, AcelRx Pharmaceuticals and Myovant Sciences; anticipated milestones of Ovid Therapeutics for the second half of this year; European Commission's approval of Akcea's TEGSEDI; Achieve Life Sciences' progress with Cytisine as an aid to smoking cessation and a regulatory event to watch out for today.

Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT

-- Alexander Kolevzon, M.D., to review additional data from company’s Phase 2 STARS trial with OV101 for the treatment of Angelman syndrome during the 65th American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting -- NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transfor...

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming investor conferences: Baird’s 2018 Global Healthcare ConferenceThe company will participate in a fireside chat on Thurs...

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming investor conferences in October: Cantor Fitzgerald Global Healthcare ConferenceThe company will give a corporate presen...

Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it will present two poster presentations and one oral presentation on OV935/TAK-935 at the American Epilepsy Society (AES) 72nd Annual Meeting, taking place from N...

Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community

NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced it has received the 2018 CDKL5 Forum Company Making a Difference Award for initiation of the Phase 2 ARCADE trial with OV935/TAK-935, and its commitment to the CDKL5 de...

Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress

-- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a registrational pathway based on positive Phase 2 STARS data -- -- OV101 in Fragile X syndrome: topline data from Phase 2 ROCKET trial in males with Fragile X syndrome expected in 2019 -- -- OV935/TAK-935 in rare development...

Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress

OV101 in Angelman syndrome: Plan to meet with U.S. FDA in the fourth quarter of 2018 to review Phase 2 STARS results and discuss next steps for program OV935/TAK-935 in rare developmental and epileptic encephalopathies: 12-week data from Phase 1b/2a study expected in fourth quarter of 2018; Enrollment initiated in two Phase 2 trials in pediatrics and adolescent ages 2 to 17 NEW YORK, Nov. 08,...

Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27

NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 11:00 a.m. EST. The conference will be held at th...

Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome

NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has initiated the Phase 2 ROCKET clinical trial evaluating OV101 for the treatment of adolescents and young adult males with Fragile X syndrome. OV101 is a nov...

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to the now fully enrolled Phase 1b/2a trial of adults with DEE

Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

-- OV935 is being investigated for the treatment of pediatric patients with Dravet or Lennox-Gastaut syndromes in the ELEKTRA trial and pediatric patients with CDKL5 deficiency or Dup15q syndromes in the ARCADE trial -- NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of p...

Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo -- -- STARS data support plans to advance OV101 development and discuss with regulatory authorities next steps for a registrational pathw...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks